CCL2 and prostate cancer: Indeed, CCL2 appears to be a promising biomarker as it was overexpressed in tissue and serum samples of prostate cancer patients [96], and its expression correlated with Gleason score and pathologic state [97], and a more aggressive phenotype [48].